1
|
Le Scornet T, Martin F, Dejoie T, Caristan A, Tessoulin B, Agard C, Touzeau C, Hamidou M, Ville S, Néel A. Facteurs pronostiques des cryoglobulinémies à composante monoclonale primitives. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Lécuyer R, Issa N, Tessoulin B, Morio F, Gabriel F, Canet E, Boutoille D, Raffi F, Camou F, Gaborit B. Épidémiologie et impact pronostique des co-infections respiratoires associées au diagnostic de pneumocystose. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Gastinne T, Bouabdallah K, Moatti H, Tessoulin B, Shiano del colella JM, Lamy T, Casasnovas O, Borel C, Stamatoullas A, Gac AC, Chaoui D, Feugier P, Delmer A, Bonnet C, Fornecker L, Lazarovici J, Bras F, Ghesquieres H, Meignan M, Traverse Glehen A, Brice P. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.111_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- T. Gastinne
- University Hospital of Nantes Hematology Nantes France
| | - K. Bouabdallah
- Hopital Haut‐Levêque Centre Hospitalier Regional Universitaire de Bordeaux Department of Hematology Pessac France
| | - H. Moatti
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| | - B. Tessoulin
- University Hospital of Nantes Hematology Nantes France
| | | | - T. Lamy
- Rennes University Hospital Department of Clinical Hematology MICA Research Unit Rennes France
| | - O. Casasnovas
- University Hospital F Mitterrand and INSERM 1231 Department of Haematology Dijon France
| | - C. Borel
- IUCT‐Oncopole CHU Toulouse Department of Haematology Toulouse France
| | - A. Stamatoullas
- Centre Henri Becquerel Department of Haematology U918 Rouen France
| | - A. C. Gac
- Centre Hospitalier Universitaire de Caen Institut d'hématologie de Basse‐Normandie Caen France
| | - D. Chaoui
- Centre Hospitalier d'Argenteuil Department of Hematology Argenteuil France
| | - P. Feugier
- Nancy University Hospital Department of Clinical Hematology INSERM 1256 Nancy France
| | - A. Delmer
- University Hospital of Reims Department of Haematology Reims France
| | - C. Bonnet
- CHU Liège, Liège Université Campus Universitaire de Sart Tilman Clinical Hematology Unit Liège Belgium
| | - Luc‐M. Fornecker
- Strasbourg University Hospital Department of Clinical Hematology Strasbourg France
| | - J. Lazarovici
- Institut Gustave Roussy Département des Innovations Thérapeutiques et Essais Précoces Villejuif France
| | - F. Bras
- CHU Henri Mondor Department of Hematology Creteil France
| | - H. Ghesquieres
- Hospices Civils de Lyon Centre Hospitalier Lyon‐Sud and Université Claude Bernard Lyon‐1 Department of Haematology Lyon France
| | - M. Meignan
- Hôpital H Mondor LYSA Imaging Creteil France
| | - A. Traverse Glehen
- Centre Hospitalier Lyon‐Sud Hospices Civils de Lyon Pathology Department cedex, France, Lyon France
| | - P. Brice
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| |
Collapse
|
4
|
Ducloyer JB, Ducloyer M, Tessoulin B, Lebranchu P, Deltour JB. [Orbital myeloid sarcoma secondary to acute myeloblastic leukemia]. J Fr Ophtalmol 2019; 43:e15-e16. [PMID: 31813551 DOI: 10.1016/j.jfo.2019.06.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Accepted: 06/25/2019] [Indexed: 11/25/2022]
Affiliation(s)
- J-B Ducloyer
- Service d'ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France.
| | - M Ducloyer
- Service de radiologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| | - B Tessoulin
- Service d'hématologie clinique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| | - P Lebranchu
- Service d'ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| | - J-B Deltour
- Service d'ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 01, France
| |
Collapse
|
5
|
Thieblemont C, Le Gouill S, Di Blasi R, Cartron G, Morschhauser F, Bachy E, Paillassa J, Bernard S, Tessoulin B, Gastine T, Fegueux N, Kanouni T, Manier S, Sesques P, Houot R, Haouin C, Tilly H, Salles G. REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2630] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - R. Di Blasi
- Hematology; APHP; Saint-Louis Hospital Paris France
| | - G. Cartron
- Hematology; CHU Montpellier; Montpellier France
| | | | - E. Bachy
- Hematology; CHU Lyon; Pierre-Benite France
| | - J. Paillassa
- Hematology; APHP; Saint-Louis Hospital Paris France
| | - S. Bernard
- Hematology; APHP; Saint-Louis Hospital Paris France
| | | | | | - N. Fegueux
- Hematology; CHU Montpellier; Montpellier France
| | - T. Kanouni
- Hematology; CHU Montpellier; Montpellier France
| | - S. Manier
- Hematology; CHU Montpellier; Montpellier France
| | - P. Sesques
- Hematology; CHU Lyon; Pierre-Benite France
| | - R. Houot
- Hematology; CHU Rennes; Rennes France
| | - C. Haouin
- Hematology; APHP; Henri Mondor Hospital, Créteil France
| | - H. Tilly
- Hematology; Centre H. Becquerel; Rouen France
| | - G. Salles
- Hematology; CHU Lyon; Pierre-Benite France
| |
Collapse
|
6
|
Le Bris Y, Theisen O, Godon C, Tiab M, Moreau A, Bossard C, Subiger F, Chiron D, Gastinne T, Tessoulin B, Maisonneuve H, Le Gouill S, Béné M. INCREASED CCND1
FISH SIGNALS ARE ASSOCIATED WITH WORSE PROGNOSIS IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.4_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Y. Le Bris
- Hematology Biology; Nantes University Hospital; Nantes France
| | - O. Theisen
- Hematology Biology; Nantes University Hospital; Nantes France
| | - C. Godon
- Hematology Biology; Nantes University Hospital; Nantes France
| | - M. Tiab
- Hematology Clinic; Centre Hospitalier Départemental de Vendée; La Roche sur Yon France
| | - A. Moreau
- Pathology; Nantes University Hospital; Nantes France
| | - C. Bossard
- Pathology; Nantes University Hospital; Nantes France
| | - F. Subiger
- Biology; Centre Hospitalier Départemental de Vendée; La Roche sur Yon France
| | - D. Chiron
- INSERM_U1232, CRCINA, INSERM, CNRS; Université d'Angers, Université de Nantes; Nantes France
| | - T. Gastinne
- Hematology Clinic; Nantes University Hospital; Nantes France
| | - B. Tessoulin
- Hematology Clinic; Nantes University Hospital; Nantes France
| | - H. Maisonneuve
- Hematology Clinic; Centre Hospitalier Départemental de Vendée; La Roche sur Yon France
| | - S. Le Gouill
- Hematology Clinic; Nantes University Hospital; Nantes France
| | - M. Béné
- Hematology Biology; Nantes University Hospital; Nantes France
| |
Collapse
|
7
|
Ferrero S, Ladetto M, Beldjord K, Drandi D, Stelitano C, Bernard S, Castagnari B, Bouabdallah K, Cesaretti M, Alvarez I, Gressin R, Ponzoni M, Tripodo C, Traverse-Glehen A, Baseggio L, Liberati A, Merli M, Tessoulin B, Patti C, Cabras M, Feugier P, Pozzi S, Zucca E, Iannitto E, Thieblemont C. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.39_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - M. Ladetto
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo; SC Ematologia; Alessandria Italy
| | - K. Beldjord
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - D. Drandi
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - C. Stelitano
- U.O.C. Ematologia; Grande Ospedale Metropolitano Bianchi Melacrino Morelli; Reggio Calabria Italy
| | - S. Bernard
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - B. Castagnari
- UOC of Hematology; Hospital Santa Maria delle Croci; Ravenna Italy
| | | | - M. Cesaretti
- University of Modena and Reggio Emilia; Department of Diagnostic, Clinical and Public Health Medicine; Modena Italy
| | - I. Alvarez
- AUSL Reggio Emilia/IRCCS; Arcispedale Santa Maria Nuova, UOC of Hematology; Reggio Emilia Italy
| | - R. Gressin
- Grenoble Alpes University Hospital; Department of Hematology; Grenoble France
| | - M. Ponzoni
- Pathology Unit; Ateneo Vita-Salute and San Raffaele Scientific Institute; Milano Italy
| | - C. Tripodo
- Department of Health Science; Human Pathology Section,Tumor Immunology Unit, University of Palermo; Palermo Italy
| | | | - L. Baseggio
- Pierre-Benite; Cytology, CHU Lyon; Lyon France
| | - A. Liberati
- University of Perugia; Oncology-Hematology, Santa Maria Hospital; Terni Italy
| | - M. Merli
- ASST Settelaghi; University Hospital Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | | | - C. Patti
- Division of Hematology; Azienda Ospedali Riuniti Villa Sofia-Cervello; Palermo Italy
| | - M. Cabras
- Ospedale Businco; Division of Hematology; Cagliari Italy
| | - P. Feugier
- University Hospital of Nancy; Department of Haematology; Nancy France
| | - S. Pozzi
- Unit of Target Therapy in Onco-Hematology and Osteoncology, University of Modena and Reggio Emilia, Department of Oncology and Hematology; Modena Cancer Center; Modena Italy
| | - E. Zucca
- Institute of Oncology Research; Università della Svizzera Italiana (USI), IOSI, Oncology Institute of Southern Switzerland and IOR; Bellinzona Switzerland
| | - E. Iannitto
- Department of Oncology; “La Maddalena”, Onco-Hematology and BMT Unit; Palermo Italy
| | | |
Collapse
|
8
|
Gaborit B, Tessoulin B, Moriot F, Lavergne R, Bretonnière C, Lecomte R, Deschanvres C, Raffi F, Boutoille D, Reignier J. Analyse des facteurs pronostiques précoces de sévérité et mortalité au cours de la pneumocystose : étude observationnelle prospective sur 5 ans. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Hematol 2017; 96:943-950. [DOI: 10.1007/s00277-017-2981-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 03/16/2017] [Indexed: 10/19/2022]
|
10
|
Tessoulin B, Eveillard M, Lok A, Chiron D, Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S, Pellat-Deceunynck C. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Rev 2017; 31:251-259. [PMID: 28284458 DOI: 10.1016/j.blre.2017.03.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 03/02/2017] [Indexed: 12/31/2022]
Abstract
TP53 deletion or mutation is frequent in B-cell malignancies and is associated with a low response rate. We describe here the p53 landscape in B-cell malignancies, from B-Acute Lymphoblastic Leukemia to Plasma Cell Leukemia, by analyzing incidence of gain or loss of function of actors both upstream and within the p53 pathway, namely MYC, RAS, ARF, MDM2, ATM and TP53. Abnormalities are not equally distributed and their incidence is highly variable among malignancies. Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. MYC gain, absent in post-GC malignancies, is frequent in B-Prolymphocytic-Leukemia, Multiple Myeloma and Plasma Cell Leukemias. RAS mutations are rare except in MM and PCL. Multiple Factorial Analysis notes that MYC deregulation is closely related to TP53 status. Moreover, MYC gain, TP53 deletion and RAS mutations are inversely correlated with survival. Based on this landscape, we further propose targeted therapeutic approaches for the different B-cell malignancies.
Collapse
Affiliation(s)
- B Tessoulin
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France.
| | - M Eveillard
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Hematology Biology Department, Nantes University Hospital, Nantes, France
| | - A Lok
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France
| | - D Chiron
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France
| | - P Moreau
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France
| | - M Amiot
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France
| | - A Moreau-Aubry
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France
| | - S Le Gouill
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France; Department of Hematology, Nantes University Hospital, Nantes, France
| | - C Pellat-Deceunynck
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, France.
| |
Collapse
|
11
|
Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillerm G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant 2016; 51:1184-90. [PMID: 27111043 DOI: 10.1038/bmt.2016.102] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 03/06/2016] [Accepted: 03/08/2016] [Indexed: 11/09/2022]
Abstract
Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell lymphoma (MCL). Despite this intensive treatment, transplant patients remain highly susceptible to relapse over time. The French SFGM-TC performed a national survey on reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) for fit relapsed/refractory patients who failed after auto-SCT (n=106). Median times of relapse after auto-SCT, and from auto-SCT to RIC-allo-SCT were 28 months and 3.6 years, respectively. Sixty per cent of patients received at least three lines of treatment before RIC-allo-SCT. Conditioning regimens for RIC-allo-SCT were heterogeneous. Twenty patients experienced grade III/IV aGvHD, extensive cGvHD was reported in 28 cases. Median follow-up after RIC-allo-SCT was 45 months. Median PFS after RIC-allo-SCT was 30.1 months and median overall survival was 62 months. Treatment-related mortality (TRM) at 1 year and 3 years were estimated at 28% and 32%, respectively. A total of 52 patients died; major causes of death were related to toxicity (n=34) and MCL (n=11). Patients in good response before RIC-allo-SCT experienced a better PFS and OS. Our work highlights the need for new RIC-allo-SCT MCL-tailored approaches to reduce TRM, and early and late relapse.
Collapse
Affiliation(s)
- B Tessoulin
- Department of Hematology, University Hospital, Nantes, France.,INSERM team 10 UMR 892, CRCNA, Nantes, France
| | - P Ceballos
- Department of Hematology, University Hospital, Montpellier, France
| | - P Chevallier
- Department of Hematology, University Hospital, Nantes, France
| | - D Blaise
- Department of Hematology, Paoli Calmettes, Marseille, France
| | - O Tournilhac
- Department of Hematology, University Hospital, Clermont-Ferrand, France
| | - J Gauthier
- Department of Hematology, University Hospital, Lille, France
| | - N Maillard
- Department of Hematology, University Hospital, Poitiers, France
| | - R Tabrizi
- Department of Hematology, University Hospital, Bordeaux, France
| | - S Choquet
- Department of Hematology, Pitie Salpetriere, Paris, France
| | - S Carras
- Department of Hematology, University Hospital, Grenoble, France
| | - N Ifrah
- Department of Hematology, University Hospital, Angers, France
| | - G Guillerm
- Department of Hematology, University Hospital, Brest, France
| | - M Mohty
- Department of Hematology, University Hospital-Saint Antoine, Paris, France
| | - H Tilly
- Department of Hematology, Centre Henri-Becquerel, Rouen, France
| | - G Socie
- Department of Hematology, Saint Louis Hospital, Paris, France
| | - J Cornillon
- Department of Hematology, Institut de Cancerologie de la Loire, Saint Etienne, France
| | - O Hermine
- Department of Hematology, Necker Hospital, Paris, France
| | - É Daguindau
- Department of Hematology, University Hospital, Besancon, France
| | - E Bachy
- Department of Hematology, University hospital, Lyon, France
| | - S Girault
- Department of Hematology, University Hospital, Limoges, France
| | - T Marchand
- Department of Hematology, University Hospital, Rennes, France
| | - L Oberic
- University Cancer Institute, Toulouse, France
| | - O Reman
- Department of Hematology, University Hospital, Caen, France
| | - C Leux
- Department of Epidemiology, University Hospital of Nantes, Nantes, France
| | - S Le Gouill
- Department of Hematology, University Hospital, Nantes, France.,INSERM team 10 UMR 892, CRCNA, Nantes, France.,Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France
| |
Collapse
|
12
|
Lassalle A, Thomaré P, Fronteau C, Mahé B, Jubé C, Blin N, Voldoire M, Dubruille V, Tessoulin B, Touzeau C, Chauvin C, Loirat M, Lok A, Bourcier J, Lestang E, Mocquet R, Barbarot V, Moreau P. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol 2016; 27:314-8. [DOI: 10.1093/annonc/mdv563] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2015] [Accepted: 11/02/2015] [Indexed: 11/14/2022] Open
|
13
|
Néel A, Bucchia M, Tessoulin B, Bressollette C, Degauque N, Agard C, Graveleau J, Godmer P, Garandeau C, Perrin F, Fakhouri F, Hamidou M. Le CMV sous tend l’expansion des TEMRA aux cours des VAA, sans influer sur la présentation ni sur l’évolution de la maladie. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Tessoulin B, Delaunay J, Chevallier P, Loirat M, Ayari S, Peterlin P, Le Gouill S, Gastinne T, Moreau P, Mohty M, Guillaume T. Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone Marrow Transplant 2014; 49:567-71. [DOI: 10.1038/bmt.2013.233] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Revised: 11/19/2013] [Accepted: 11/26/2013] [Indexed: 11/09/2022]
|
15
|
Tessoulin B, Beyne-RAuzy O, Guerci A, Gyan E, Hunault M, Ianotto J, Shanti A, Stamatoullas A, Dreyfus F, Fenaux P, Delaunay J. P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70356-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|